S. Arbuck

发表

[New guidelines to evaluate the response to treatment in solid tumors].

M. Christian, E. Eisenhauer, L. Rubinstein, 2000, Bulletin du cancer.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

L. Schwartz, D. Sargent, L. Dodd, 2009, European journal of cancer.

32 INVITED New response evaluation criteria in solid tumors: revised RECIST guideline version 1.1

L. Schwartz, D. Sargent, D. Lacombe, 2008 .

Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms

E. Sausville, S. Arbuck, G. Melillo, 2003, Anti-cancer drugs.

Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.

E. Sausville, S. Arbuck, S. Swain, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.

E. Sausville, S. Arbuck, S. Akinaga, 1998, Cancer research.

Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target.

L Meijer, L. Meijer, E. Sausville, 1999, Pharmacology & therapeutics.

New guidelines to evaluate the response to treatment in solid tumors

M. van Glabbeke, M. Christian, E. Eisenhauer, 2000, Journal of the National Cancer Institute.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

M Van Glabbeke, J Verweij, M. van Glabbeke, 2000, Journal of the National Cancer Institute.

A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms

E. Sausville, M. Monga, S. Arbuck, 2014, Cancer Chemotherapy and Pharmacology.

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

M. Christian, L. Rubinstein, D. Zaharevitz, 2001, British Journal of Cancer.

Accelerated titration designs for phase I clinical trials in oncology.

R Simon, R. Simon, M. Christian, 1997, Journal of the National Cancer Institute.

Interspecies differences in in vitro etoposide plasma protein binding.

S. Arbuck, C. Stewart, R. Fleming, 1991, Biochemical pharmacology.

A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.

S. Steinberg, S. Arbuck, J. Grem, 1993, Cancer research.

Flow cytometric analysis of DNA aneuploidy in primary and metastatic human solid tumors.

N. Petrelli, W. Greco, S. Arbuck, 1984, Cytometry.

Clinical development of Taxol.

M. Christian, S. Arbuck, K. E. Cole, 1993, Journal of the National Cancer Institute. Monographs.

Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.

S. Arbuck, C. Takimoto, J. Grem, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Taxol: the first of the taxanes, an important new class of antitumor agents.

S. Arbuck, N. Onetto, E. Rowinsky, 1992, Seminars in oncology.

Topotecan treatment of adults with primary malignant glioma

R. McLendon, A. Friedman, S. Arbuck, 1999, Cancer.

Clinical applications of the camptothecins.

S. Arbuck, C. Takimoto, J. Wright, 1998, Biochimica et biophysica acta.

Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial.

J. Decaprio, S. Arbuck, R. Mayer, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Progress report on studies of FAM-CF for gastric cancer and intraperitoneal administration of FUra-CF followed by cisplatin (DDP).

H. Nava, S. Arbuck, Y. Rustum, 1988, Advances in experimental medicine and biology.

Evaluation of the nephrotoxicity of iproplatin (CHIP) in comparison to cisplatin by the measurement of urinary enzymes

S. Arbuck, L. Pendyala, S. Lele, 2004, Cancer Chemotherapy and Pharmacology.

Proliferative characteristics of primary and metastatic human solid tumors by DNA flow cytometry.

W. Greco, S. Arbuck, Y. Rustum, 1984, Cytometry.

Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.

R. Bast, L. Burke, S. Horning, 2007, Gynecologic oncology.

A phase II trial of 5‐fluorouracil, doxorubicin, mitomycin C, and leucovorin in advanced gastric carcinoma

H. Nava, S. Arbuck, Y. Rustum, 1990, Cancer.

National Cancer Institute Clinical Trials Program in Colorectal Cancer

S. Arbuck, R. Kaplan, B. Conley, 2009, Cancer Chemotherapy and Pharmacology.

Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study.

S. Arbuck, H. Averette, S. Wadler, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical development of anticancer agents from natural products

M. Christian, S. Arbuck, D. Parkinson, 1994, Stem cells.

Changes in the clearance of total and unbound etoposide in patients with liver dysfunction.

W. Evans, S. Arbuck, C. Stewart, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relation of systemic exposure to unbound etoposide and hematologic toxicity

W. Evans, S. Arbuck, C. Stewart, 1991, Clinical pharmacology and therapeutics.

A reassessment of cardiac toxicity associated with Taxol.

M. Christian, H. Gibbs, S. Arbuck, 1993, Journal of the National Cancer Institute. Monographs.

Seizures associated with leucovorin administration in cancer patients.

N. Petrelli, S. Arbuck, N. Meropol, 1995, Journal of the National Cancer Institute.

Clinical status and optimal use of topotecan.

S. Arbuck, C. Takimoto, Chris H. Takimoto, 1997, Oncology.

Camptothecin and Its Analogs

S. Arbuck, I. Dimery, F. Muggia, 1996 .

Overview of chemotherapy for pancreatic cancer

S. Arbuck, 1990, International journal of pancreatology : official journal of the International Association of Pancreatology.

Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin.

N. Petrelli, S. Arbuck, Y. Rustum, 1987, NCI monographs : a publication of the National Cancer Institute.

A phase II trial of 5-fluorouracil and high-dose intravenous leucovorin in gastric carcinoma.

H. Nava, S. Arbuck, Y. Rustum, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Free and liposomal doxorubicin treatment of intraperitoneal colon 26 tumor: therapeutic and pharmacologic studies.

S. Arbuck, E. Mayhew, M. Cimino, 1990, Selective cancer therapeutics.

Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer.

D. Amadori, G. Sledge, S. Arbuck, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical trials referral resource. Trials of topotecan.

B. Cheson, S. Arbuck, P. Phillips, 1995, Oncology.

An overview of topoisomerase I-targeting agents.

S. Arbuck, C. Takimoto, 1998, Seminars in hematology.

Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma.

S. Steinberg, A. Chen, S. Arbuck, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New drugs in non-Hodgkin's lymphoma.

M. Christian, B. Cheson, S. Arbuck, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models

E. Sausville, S. Arbuck, A. Senderowicz, 2009, Cancer Chemotherapy and Pharmacology.

Altered protein binding of etoposide in patients with cancer

W. Evans, S. Arbuck, C. Stewart, 1989, Clinical pharmacology and therapeutics.

A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days

S. Arbuck, J. Cowens, R. Huben, 2004, Cancer Chemotherapy and Pharmacology.

Primary therapy of multiple myeloma with paclitaxel (taxol).

M. Dimopoulos, S. Arbuck, D. Weber, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel (Taxol) in breast cancer.

S. Arbuck, A. Dorr, M. Friedman, 1994, Hematology/oncology clinics of North America.

Camptothecin and its analogs. An overview of their potential in cancer therapeutics.

S. Arbuck, I. Dimery, F. Muggia, 1996, Annals of the New York Academy of Sciences.

#420 Common toxicity criteria (ctc) version 2.0: highlights and tools

S. Arbuck, A. Setser, S. Ivy, 1999 .

9‐Aminocamptothecin and Beyond

S. Arbuck, C. Takimoto, H. Hochster, 1996, Annals of the New York Academy of Sciences.

A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.

S. Steinberg, P. Johnston, S. Arbuck, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Taxol®: science and applications.

Michael L. Shuler, Haeil Park, William C. Rose, 1995 .

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.

E. Sausville, S. Arbuck, A. Senderowicz, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacologic studies of intraperitoneal leucovorin and 5-fluorouracil in patients with advanced cancer.

H. Nava, S. Arbuck, Y. Rustum, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New targets for cancer chemotherapy.

M. Hidalgo, J. Dancey, S. Arbuck, 2002, Cancer chemotherapy and biological response modifiers.

Selectivity of the micro‐leukocyte adherence inhibition assay in pancreatic cancer

S. Arbuck, H. Douglass, M. Goldrosen, 1979, Cancer.

Cancer Drugs and Cancer Drug Development for the New Millennium

J. Dancey, S. Arbuck, 2000 .

Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.

J. Manola, S. Arbuck, A. Benson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.

E. Sausville, M. Christian, S. Arbuck, 1997, Seminars in oncology.

Clinical trial designs for cytostatic agents: are new approaches needed?

R Simon, E L Korn, R. Simon, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

S. Steinberg, E. Sausville, S. Arbuck, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.

E. Sausville, E. Sausville, S. Arbuck, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II Trial of 9-Aminocamptothecin as a 72-h Infusion in Cutaneous T-Cell Lymphoma

S. Arbuck, A. Argiris, T. Kuzel, 2001, Investigational New Drugs.

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.

E. Estey, M. Andreeff, S. Arbuck, 1996, Blood.

Clinical toxicities encountered with paclitaxel (Taxol).

E. Eisenhauer, S. Arbuck, R. Donehower, 1993, Seminars in oncology.

Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients.

S. Arbuck, C. Takimoto, J. Grem, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for three weeks in metastatic colorectal carcinoma

D. Moore, S. Arbuck, R. Winn, 1998, Investigational New Drugs.

Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.

E. Estey, B. Cheson, S. Arbuck, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma.

D. Moore, S. Arbuck, R. Winn, 1998, Investigational new drugs.

Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma.

S. Arbuck, R. Winn, R. Pazdur, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients.

S. Arbuck, C. Takimoto, J. Grem, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.

S. Arbuck, K. Bhalla, A. M. Ibrado, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Etoposide pharmacokinetics in patients with normal and abnormal organ function.

W. Evans, S. Arbuck, H. Douglass, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

myelodysplastic syndrome and chronic myelomonocytic leukemia Topotecan, a topoisomerase I inhibitor, is active in the treatment of

M. Andreeff, S. Arbuck, H. Kantarjian, 2011 .

Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996.

S. Arbuck, S G Arbuck, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Taxol: a history of pharmaceutical development and current pharmaceutical concerns.

J. W. Wilson, S. Arbuck, J. Adams, 1993, Journal of the National Cancer Institute. Monographs.

A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon.

S. Steinberg, S. Arbuck, J. Grem, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Clinical Pharmacology of Flavopiridol following a 72-Hour Continuous Infusion

E. Sausville, S. Arbuck, A. Senderowicz, 2003, The Annals of pharmacotherapy.

A randomized phase 2 trial comparing 3‐hour versus 96‐hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer

P. Thall, G. Hortobagyi, V. Valero, 2010, Cancer.

Factors affecting in vitro protein binding of etoposide in humans.

W. Evans, S. Arbuck, C. Stewart, 1992, Journal of pharmaceutical sciences.

Taxol plus recombinant human granulocyte colony stimulating factor as salvage chemotherapy for metastatic breast cancer

C. Hudis, L. Norton, S. Arbuck, 1994 .

Taxol and Recombinant Human Granulocyte Colony‐Stimulating Factor, an Active Regimen as Initial Therapy for Metastatic Breast Cancer

C. Hudis, L. Norton, S. Arbuck, 1993, Annals of the New York Academy of Sciences.

Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients.

W. Evans, S. Arbuck, C. Stewart, 1990, Cancer research.

Interleukin-2 lymphokine-activated killer cell therapy of non-Hodgkin's lymphoma and Hodgkin's disease.

S. Arbuck, H. Watanabe, L. Vaickus, 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

SPECIAL ARTICLE New Guidelines to Evaluate the Response to Treatment in Solid Tumors

M. Christian, E. Eisenhauer, L. Rubinstein, 2000 .

DNA topoisomerase I inhibitors.

S. Arbuck, C. Takimoto, L. Kieffer, 1997, Cancer chemotherapy and biological response modifiers.

Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF.

S. Arbuck, P. O'dwyer, L. Miller, 1996, European journal of cancer.

Clinical T rial D esigns f or C ytostatic A gents: A re N ew Approaches N eeded?

R. Simon, M. Christian, E. Korn, 2001 .

Current dosage and schedule issues in the development of paclitaxel (Taxol).

M. Christian, S. Arbuck, N. Onetto, 1993, Seminars in oncology.

Chemotherapy for pancreatic cancer.

S. Arbuck, 1990, Bailliere's clinical gastroenterology.

Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma.

S. Steinberg, S. Arbuck, R. Beveridge, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KAPOSI'S SARCOMA RESPONSE CRITERIA: ISSUES IDENTIFIED BY THE NATIONAL CANCER INSTITUTE, FOOD AND DRUG ADMINISTRATION, AND THE AIDS MALIGNANCY CONSORTIUM

R. Wittes, S. Arbuck, A. Murgo, 1997 .

Clinical Trial Designs for Cytostatic Agents and Agents Directed at Novel Molecular Targets

E. Korn, E. Eisenhauer, L. Rubinstein, 2006 .

Paclitaxel: what schedule? What dose?

S. Arbuck, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

5-FU/leucovorin: biochemical modulation that works?

S. Arbuck, 1987, Oncology.

A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients

A. Chen, S. Arbuck, C. Takimoto, 2001, Cancer Chemotherapy and Pharmacology.

DNA topoisomerase I poisons.

S. Arbuck, C. Takimoto, J. Wright, 1999, Cancer chemotherapy and biological response modifiers.

Taxol (paclitaxel): future directions.

S. Arbuck, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Workshop on phase I study design *

S. Arbuck, 2005 .

Overview of clinical trials using 5‐fluorouracil and leucovorin for the treatment of colorectal cancer

S. Arbuck, Susan G. Arbuck, 1989, Cancer.

A phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with refractory neoplasms

E. Sausville, S. Arbuck, A. Senderowicz, 1998 .